People of African descent born in Europe face systemic racism in the EU, stated a report by the European Union Agency for Fundamental Rights. Moreover, European institutions are struggling to lead by example. EURACTIV France reports. Reported by EurActiv 1 hour ago.

First Audit in Company’s New Manufacturing Facility Shows Compliance with GMP Guidelines

AUSTIN, Texas, Dec. 03, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced a successful GMP (Good Manufacturing Practices) audit by Eurofins Amatsigroup. The audit was conducted in connection with XBiotech’s distribution in Europe of its US-manufactured biological drug product. XBiotech manufactures bermekimab at its campus facility in Austin, Texas and regularly ships the drug to clinics in various countries in the European Union and the United Kingdom. Drugs manufactured outside of Europe may only be distributed in Europe through a qualified organization that can assure quality of drug product and manufacturing practices. The Company recently retired its old operations, which included a GMP manufacturing facility, consolidating its programs in a state-of-the-art manufacturing and R&D center on its campus in Austin. This is the first audit of the new facility.Norma Gonzalez, XBiotech’s Vice President of Quality, commented, “We are revolutionizing the manufacturing of biological drugs in many ways, including in terms of robustness and ease of GMP compliance. We were pleased to be able to once again demonstrate this in the audit process.”

XBiotech  recently consolidated operations at its new headquarter facility in Austin, Texas. Operations are now exclusively housed in one complex that includes a custom-built state-of-the-art manufacturing operation, R&D laboratories and administrative space. XBiotech’s facilities are located on a 48 acre estate located only minutes from Austin’s city center. XBiotech  developed manufacturing technology using bioreactors designed and built by the Company, employing its technology to dramatically reduced capital costs, plant and equipment operating complexity, and improve production flexibility compared to existing manufacturing commonly used to produce marketed biologics. XBiotech currently produces all of its clinical drug material and plans to manufacture commercial drug product from its Austin headquarters.

*About True Human™ Therapeutic Antibodies
*XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

*About XBiotech
*XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

*Cautionary Note on Forward-Looking Statements
*This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may,""will,""should,""would,""could,""expects,""plans,""contemplate,""anticipates,""believes,""estimates,""predicts,""projects,""intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

*Contact*
Ashley Otero
aotero@xbiotech.com
512-386-2930

Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/0558d76a-c4f4-40d7-8c41-808480a0a320
http://www.globenewswire.com/NewsRoom/AttachmentNg/593d4948-7cd5-452e-8cc3-fa0745641503
http://www.globenewswire.com/NewsRoom/AttachmentNg/033b92f0-7956-49d8-bf22-b6984b45211a Reported by GlobeNewswire 59 minutes ago.

According to the report, the global emergency medical service product market was valued at approximately USD 20.56 billion in 2017 and is expected to reach around USD 31.54 billion by 2024, growing at a CAGR of 6.77 % between 2018 and 2024.

New York, NY, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled *“Emergency Medical Service Product Market by Type (Patient Monitoring Equipment, Patient Handling Equipment, Wound Care Products, Infection Control Consumables, Personal Protection Equipment & Life Support, and Emergency Resuscitation Equipment), by Application (Cardiac Care, Trauma Injuries, Respiratory Care, Oncology, and Others), and by End-User (Hospitals & Trauma Centers, Ambulatory Surgical Centers, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2024”*. According to the report, the global emergency medical service product market was valued at approximately USD 20.56 billion in 2017 and is expected to reach around USD 31.54 billion by 2024, growing at a CAGR of 6.77 % between 2018 and 2024.

The emergency medical service is an important part of the healthcare system, especially for people who suffer sudden and unexpected emergencies. Emergency medical service is provided by local government and private entities within a geographic area, or by volunteer organizations.

*Browse through 41 Tables & 12 Figures spread over 110 Pages and in-depth TOC on “Global Emergency Medical Service Product Market: Industry Type, Size, Share, Trends and Forecast, 2018–2024”.*

*Request Free Sample Report of Global Emergency Medical Service Product Market Report @* https://www.zionmarketresearch.com/sample/emergency-medical-service-product-market

Since the last decade, major scientific advancements made in clinical practice have brought relentless changes to the emergency medical care. These innovations include the large-scale adoption of advanced equipment, such as the electrocardiogram monitor, pulse oximeter, CPR devices, and better drugs/medications. Additionally, ambulances are now being equipped with advanced radio communication systems, computers, and other patient care equipment. Emergency medical technicians and paramedics are now allowed to use advanced medications and protocols to provide better medical care for their patients. This includes new drugs to treat heart attacks, drug overdoses, and strokes. These advances are likely to drive the expansion of the emergency medical service product market.

However, the high costs of emergency medical equipment and a dearth of trained medical professionals are restraining the development of the emergency medical service product market.

*Download Free Report PDF Brochure: *https://www.zionmarketresearch.com/requestbrochure/emergency-medical-service-product-market

By type, this market is segmented into patient handling equipment, personal protection equipment, wound care products, patient monitoring equipment, infection control consumables, and life support and emergency resuscitation equipment. The life support and emergency resuscitation equipment segment are likely to account for the largest share of the emergency medical service product market. The patient monitoring equipment segment was the fastest growing segment and is likely to witness a substantial increase in revenue, owing to large-scale adoption in medical facilities.

By application, the emergency medical service product market is divided into trauma injuries cardiac care, oncology, respiratory care, and others. The cardiac care is projected to account for the largest share and grow at the highest CAGR in the forecast time period. Increasing prevalence of cardiac arrest due to cardiovascular diseases and a growing number of physical traumas are likely to benefit the emergency medical service product market in the upcoming years. This, in turn, is projected to positively impact the emergency medical service product market in the near future. However, the high cost of emergency medical service equipment might hinder this market’s growth. Increasing number of hospitals along with growing government investments made for healthcare infrastructure and medical services are expected to present lucrative opportunities in the forecast time period.

*Request for The Discount on This Report: *https://www.zionmarketresearch.com/requestdiscount/emergency-medical-service-product-market

The end-user segment includes hospitals and trauma centers, ambulatory surgical centers, and others. The hospitals and trauma centers segment dominated the market and accounted for the largest share in 2017, owing to high rates of hospital admission due to the growing incidences of heart disorders and traumatic injuries.

Europe is likely to be the second largest regional market and show strong growth in the upcoming years. The European emergency medical service product market is driven by the presence of government regulated emergency care providers. The UK accounts for a major market share and was the fastest growing country in Europe in 2017. This growth can be attributed to the easy availability of the emergency medical services and increased incidences of cardiac arrests. Heart disease is the number one death cause in the UK. According to the HEART UK, every year, more than 160,000 people die from heart and circulatory diseases.

Browse the full *"Emergency Medical Service Product Market by Type (Patient Monitoring Equipment, Patient Handling Equipment, Wound Care Products, Infection Control Consumables, Personal Protection Equipment & Life Support, and Emergency Resuscitation Equipment), by Application (Cardiac Care, Trauma Injuries, Respiratory Care, Oncology, and Others), and by End-User (Hospitals & Trauma Centers, Ambulatory Surgical Centers, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2024"* report at https://www.zionmarketresearch.com/report/emergency-medical-service-product-market

The Asia Pacific was the fastest growing market in 2017 and is likely to witness rapid growth in the near future. This growth can be attributed to the rising geriatric population, growing incidences of chronic diseases, and increased adoption of medical devices in the healthcare sector. Rapid developments related to healthcare system reforms in the Asia Pacific countries, such as India and China, has boosted the emergency medical service product market in this region. Emergency medical services are becoming readily available in the urban areas provided by private and public funded hospitals, self-help groups, and institutions of religious practice that run ambulance services. Rising awareness regarding the use of medical devices and growing investments made in the development of emergency medical services are driving the growth of Asia Pacific emergency medical service product market. The Latin American market is anticipated to grow at a significant rate, owing to the thriving healthcare infrastructure. The Middle East and Africa are estimated to witness steady growth in this market during the forecast time period.

Some key players operating in the global emergency medical service product market include Stryker, Medtronic, Asahi Kasei, Cardinal Health, Philips, GE Healthcare, Smith & Nephew, 3M, Smiths Medical, Becton, Dickinson and Company, Johnson & Johnson, B. Braun, and C. R. Bard.

*Inquire more about this report before purchase @ *https://www.zionmarketresearch.com/inquiry/emergency-medical-service-product-market

*This report segments the global emergency medical service product market as follows:*

*Global Emergency Medical Service Product Market: Type Segment Analysis*

· Life Support and Emergency Resuscitation Equipment
· Patient Monitoring Systems
· Wound Care Consumables
· Patient Handling Equipment
· Infection Control Supplies
· Personal Protection Equipment

*Global Emergency Medical Service Product Market: Application Segment Analysis*

· Cardiac Care
· Trauma Injuries
· Respiratory Care
· Oncology
· Others

*Global Emergency Medical Service Product Market: End-User Segment Analysis*

· Hospitals & Trauma Centers
· Ambulatory Surgical Centers
· Others

*Global Emergency Medical Service Product Market: Regional Segment Analysis*

· North America

· The U.S.

· Europe

· UK
· France
· Germany

· Asia Pacific

· China
· Japan
· India

· Latin America

· Brazil

· The Middle East and Africa

*Related Reports:*

· *Connected Healthcare Market: *https://www.zionmarketresearch.com/report/connected-healthcare-market
· *Tissue Diagnostic Market:* https://www.zionmarketresearch.com/report/tissue-diagnostic-market
· *Fertility Services Market:* https://www.zionmarketresearch.com/report/fertility-services-market
· *Healthcare CRM Market:* https://www.zionmarketresearch.com/report/healthcare-crm-market
· *Multiplex Biomarker Imaging Market: *https://www.zionmarketresearch.com/report/multiplex-biomarker-imaging-market             

*About Us:*

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

*Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research
*Follow Us Twitter: *https://twitter.com/zion_research

*Blog:* http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com

*Contact Us:*

Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
*Email:* sales@zionmarketresearch.com

*Website:* https://www.zionmarketresearch.com

* Blog:* http://zmrblog.com Reported by GlobeNewswire 59 minutes ago.

MONTREAL, Dec. 03, 2018 (GLOBE NEWSWIRE) -- PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF), a TSX Venture 50® high-tech company, (the "Company", the “Corporation” or "PyroGenesis") a Company that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, is pleased to announce today that, further to a Press Release dated October 25^th, 2018, the zinc paid-for-demonstration of DROSRITE™ system (the “System”) is now complete, and the results confirm PyroGenesis’ DROSRITE™ System’s commercial application to zinc dross. The Client is one of India’s biggest primary smelters and has an estimated need of upwards of ten (10) Systems within its umbrella of companies.The tests have been completed and demonstrate that DROSRITE™ is successful in recovering 98% of metal from zinc dross. This is comparable to that from the application of DROSRITE™ to aluminum dross. The analyses were conducted independently by the Client. The results indicate that the quality of the zinc is excellent, and the contaminants in the residue, such as chlorides, are significantly reduced. In addition, the System is easier to operate with zinc, when compared to aluminum, due to the lower melting point of zinc.

“We are buoyed by these results,” said Mr. Alex Pascali, Business Development Manager of PyroGenesis. “DROSRITE™ is clearly attracting a lot of attention, specifically with respect to tolling. As has been mentioned, we are in several strategic discussions with smelters, and after our recent business development trip to Europe and Asia, this has accelerated. We must, at some point, consider offering only DROSRITE™ tolling services, given the recurring benefits of such a strategy.”

“These zinc dross results, together with our recent success in the aluminum dross market, confirm that our proprietary DROSRITE™ System is a game changer,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “Not only have we proven the commercial application of PyroGenesis’ DROSRITE™ System to aluminum dross, but we have, today, demonstrated the same for zinc dross, which significantly increases the value of the Company’s DROSRITE™ System.”

With the successful completion of this zinc demonstration, PyroGenesis can now target zinc smelters around the world. Of note, the price of zinc is approximately 33% higher than that of aluminum.

PyroGenesis’ DROSRITE™ System is a salt-free, cost-effective, sustainable process for maximizing metal recovery from dross, a waste generated in the metallurgical industry. PyroGenesis’ patented process avoids costly loss of metal while reducing a smelter’s carbon footprint and energy consumption, providing an impressive return on investment. The System has been designed to process and recover valuable metal such as aluminum, zinc and copper from dross.

*About PyroGenesis Canada Inc.*

PyroGenesis Canada Inc., a TSX Venture 50^® high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m^2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "in the process" and other similar expressions which constitute "forward- looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation's current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation's ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

For further information please contact: Clémence Bertrand-Bourlaud, Marketing Manager/ Investor Relations, Phone: (514) 937-0002, E-mail: ir@pyrogenesis.com

RELATED LINKS: http://www.pyrogenesis.com/

  Reported by GlobeNewswire 39 minutes ago.

Dublin, Dec. 03, 2018 (GLOBE NEWSWIRE) -- The "Global Automotive Control Panel Market Analysis & Trends - Industry Forecast to 2027" report has been added to *ResearchAndMarkets.com's* offering.

The Global Automotive Control Panel Market is poised to grow strong during the forecast period 2017 to 2027.

Some of the prominent trends that the market is witnessing include development of solar sunroofs in cars and growing demand for cabin comfort & convenience features.

This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.
*
*The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc.

*Scope of the Report*· Based on Control Panel Type, the market is fragmented into Push Button, Manual and Touch Screen.
· On the bases of Vehicle Type, the market is bifurcated into Heavy Commercial Vehicle, Passenger Car and Light commercial vehicles.
· Depending on Product, the market is categorized into Plastic, Metal and Other Products.
· Amongst Component, the market is segregated into Door Light, Side Mirror, Smart Roof, Roof Light, Rotary Switch, Touch Pad, Driver Monitoring Camera, Locking Function, Roof Control, Electric Windows and Other Components.

*Report Highlights:*

· The report provides a detailed analysis on current and future market trends to identify the investment opportunities
· Market forecasts till 2027, using estimated market values as the base numbers
· Key market trends across the business segments, Regions and Countries
· Key developments and strategies observed in the market
· Market Dynamics such as Drivers, Restraints, Opportunities and other trends
· In-depth company profiles of key players and upcoming prominent players
· Growth prospects among the emerging nations through 2027
· Market opportunities and recommendations for new investments

*Key Topics Covered:*

*1 Market Outline*
1.1 Research Methodology
1.2 Market Trends
1.3 Regulatory Factors
1.4 Product Analysis
1.5 Strategic Benchmarking
1.6 Opportunity Analysis

*2 Executive Summary*

*3 Market Overview*
3.1 Current Trends
3.1.1 Development of Solar Sunroofs in Cars
3.1.2 Growing Demand for Cabin Comfort & Convenience Features
3.1.3 Recent Technological Developments in Automotive Control Panel
3.1.4 Growth Opportunities/Investment Opportunities
3.2 Drivers
3.3 Constraints
3.4 Industry Attractiveness

*4 Automotive Control Panel Market, By Control Panel Type*
4.1 Push Button
4.2 Manual
4.3 Touch Screen

*5 Automotive Control Panel Market, By Vehicle Type*
5.1 Heavy Commercial Vehicle
5.2 Passenger Car
5.3 Light commercial vehicles

*6 Automotive Control Panel Market, By Product*
6.1 Plastic
6.2 Metal
6.3 Other Products

*7 Automotive Control Panel Market, By Component*
7.1 Door Light
7.2 Side Mirror
7.3 Smart Roof
7.4 Roof Light
7.5 Rotary Switch
7.6 Touch Pad
7.7 Driver Monitoring Camera
7.8 Locking Function
7.9 Roof Control
7.10 Electric Windows
7.11 Other Components

*8 Automotive Control Panel Market, By Geography*
8.1 North America
8.1.1 US
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 France
8.2.2 Germany
8.2.3 Italy
8.2.4 Spain
8.2.5 UK
8.2.6 Rest of Europe
8.3 Asia Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Australia
8.3.5 New Zealand
8.3.6 Rest of Asia Pacific
8.4 Middle East
8.4.1 Saudi Arabia
8.4.2 UAE
8.4.3 Rest of Middle East
8.5 Latin America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Rest of Latin America
8.6 Rest of the World (RoW)
8.6.1 South Africa
8.6.2 Others

*9 Key Player Activities*
9.1 Mergers & Acquisitions
9.2 Partnerships, Joint Venture's, Collaborations and Agreements
9.3 Product Launch & Expansions
9.4 Other Activities

*10 Leading Companies*
10.1 Delphi Automotive PLC
10.1 Toyota Boshoku Corporation
10.1 Calsonic Kansei Corporation
10.1 Hyundai Mobis Co., Ltd
10.1 Johnson Controls, Inc
10.1 Continental AG
10.1 Lear Corporation
10.1 Magna International Inc.
10.1 Faurecia S.A
10.10 Valeo S.A
10.11 Ford Motor Company
10.12 Groupe PSA
10.13 Renault
10.14 Navistar International
10.15 TATA Motors
10.16 Volvo Group

For more information about this report visit https://www.researchandmarkets.com/research/x5k6m3/global_automotive?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Automotive Parts, Telematics and Vehicle Electronics Reported by GlobeNewswire 30 minutes ago.

Pioneer of Industrial Internet Cybersecurity Solutions Ready to Boost International Expansion

NEW YORK and LYON, France, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Sentryo.net, a pioneer of Industrial Internet cybersecurity, which was named “Cool Vendor in Industrial IoT and OT Security, 2018” by Gartner, Inc. has raised €10M in Series A Financing. The round was raised in two stages with four new investors: Sopra Steria and BNP Paribas Développement in the first half of 2018 and Omnes and Alliance Entreprendre in November 2018. Investors from the first seed round: Breed Reply, ACE Management, and Kreaxi also participated in this series. To date, Sentryo has raised 13M€.Sentryo helps organizations embrace the promises of Industry 4.0 innovations by keeping their industrial operations safe from cyber attacks. Sentryo’s ICS CyberVision award winning platform gives control engineers comprehensive visibility on their industrial control systems, detects anomalies and accelerates response to cybersecurity incidents keeping them ahead of cyber threats.

Operational Technology (OT) cybersecurity is a fast-growing market. Organizations are connecting their control systems to the world as they are leveraging digitalization to transform their industrial operations but they have not been designed to handle cyber attacks. As they are increasing their exposure to cyber risk, they must gain in-depth visibility on what’s going on, track anomalies to mitigate risks and detect critical events.

Founded in 2014, Sentryo has already won a wide international portfolio of customers in critical markets such as Energy, Oil & Gas, Manufacturing, Transportation, Process Industries and Building Management. Its rapid growth is fuelled by its strategic partnerships with large cybersecurity service providers and major control engineering vendors. This new fund raising will permit Sentryo to accelerate its expansion in Europe and North America and boost its technology leadership.

“We are proud to welcome new high-profile investors as well as to receive renewed trust from initial investors. We have put together a great team of experts and delivered technological products that our customers and partners love. Our investors have been convinced by our vision and our ability to execute,” said Thierry Rouquet, Sentryo’s Co-founder and President. “Customers rely on Sentryo to empower their control engineers to protect their industrial assets and work with IT managers to include OT in their cyber-security strategy.”

“Corporations are facing a great challenge when trying to extend their cybersecurity best practices to their industrial infrastructures,” explains Arnaud Cailleau, Cybersecurity VP at Sopra Steria. “Technology designed to protect IT systems from cyber attacks cannot cope with the specificities of industrial systems. We also need security solutions that professionals can use in their process control and industrial maintenance workflows. By putting OT staff at the front line of defense and giving them the tools to collaborate with IT experts, Sentryo is making a huge contribution to the protection of our industries.”  

*About SENTRYO:*
Sentryo is the pioneer in solutions dedicated to managing the cyber risk of M2M networks and industrial control systems. Sentryo’s ICS CyberVision empowers operation engineers as the front line of defense to ensure integrity, continuity and security of their industrial processes. It leverages unique AI algorithms to give them comprehensive visibility on their industrial assets so they can easily identify vulnerabilities, detect anomalies in real time and work with IT to fight cyber-attacks. Sentryo’s ICS CyberVision is used every day by large corporations in the energy, manufacturing and transportation markets. Sentryo is headquartered in France and has a worldwide presence including offices and partners in Europe, North and South America, Middle-East and Asia.  Website : http://www.sentryo.net

*About ACE MANAGEMENT:
*ACE Management is a private portfolio investment management company, which has specialised for the past 20 years in private equity investments in tech companies in the aerospace, maritime, defence and security sectors. The company manages 7 funds representing close to €440m of AUM, including Aerofund (I, II & III), Financière de Brienne, Sécurité and Atalaya. Investors in these funds include European industrial groups (Airbus, Safran, Airbus Group, Airbus Helicopters, Thales, Naval Group, CEA, Louis Dreyfus Armateurs and Areva), alongside institutional investors (Bpifrance, FTQ, GICAN, CIMR, Société Générale, Crédit Agricole, CIC, AXA and Crédit Coopératif) and also regional authorities (Occitanie & Nouvelle Aquitaine, Pays de la Loire, Centre-Val de Loire).
Website : http://www.acemanagement.fr

*About** BNP PARIBAS DÉVELOPPEMENT:
*BNP Paribas Développement, a BNP Paribas Group subsidiary founded in 1988, invests its own capital directly in promising small and medium-sized enterprises and mid-cap companies.  As a minority shareholder in these target companies, BNP Paribas Développement seeks to promote their growth and ensure their longer-term prosperity by facilitating ownership transfer. In addition to providing financial resources so as to ensure the stability of any company in which BNP Paribas Développement invests, we also see our mission in helping the company management team to achieve its medium-term strategic plans.  As a minority shareholder, our approach is to assist our partner with an appropriate level of governance, based on our experience of managing a portfolio of some 300 company shareholdings and backed by the strength of a world-class financial group, but without interfering in the day-to-day running of the partner company.  Our policy of investing our own capital allows us to provide our partner companies with long-term backing suited to the nature of the particular business and its goals, and also enables us to act as an intermediary in such deals as capital re-organisations and external growth operations. Website: http://www.bnpparibasdeveloppement.com

*About BREED REPLY:
*Breed Reply, Reply's active operational investor, funds and supports the development of early-stage companies in the Internet of Things (IoT) in Europe and the USA. Based in London, with operational offices in Milan, Breed Reply supports entrepreneurs and young talent by quickly bringing new ideas to the market. This is done via three fundamental services: funding at early-stage level; active operational involvement with significant know how transfer of business, managerial and technological expertise; and go-to market support through the extensive Reply network. Breed Reply’s focus is the Internet of Things over all markets, with their current portfolio in Fitness & Wellness, Smart Building & Cities, Security, Industrial IoT and Platforms. Website : http://www.reply.com

*About KREAXI:
*KREAXI is one of the top French Venture Capital specialist investing in early stage start-ups, managing € 250m through pan-european funds (€ 170m) and regional funds (€ 80m). KREAXI has backed more than 550  companies in the last 30 years (out of which 24 went public), has an active portfolio of 80 companies, and a team of 15 professionals based in Lyon, Paris and Frankfurt. Website : http://www.kreaxi.com

*About ALLIANCE ENTREPRENDRE:
*Alliance Entreprendre is a Paris-based Management Company specialized in Private Equity. Founded in 1995, the firm manages and advises over €440M of assets for institutional and retail investors. Alliance Entreprendre is dedicated to the Small Cap market through three activities: buyout, growth and venture capital, and has invested in more than 220 companies since inception. Website : http://www.allianceentreprendre.com

*About OMNES:
*Omnes is a leading Paris-based European investor in private equity and infrastructure. With €3.6 billion of assets under management, Omnes provides SMEs with the capital needed to finance growth. The firm has dedicated investment teams across three key areas: Venture Capital, Buyout & Growth Capital and Infrastructure. With more than 30 trade sales and nearly 15 IPOs in 19 years (including Novaled, Biovex, arGEN-X and Direct Energie), Omnes Venture Capital  team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors. Its current portfolio includes BlaBlaCar, Bankin', Scality, Pixium and Sigfox. Omnes is owned by its employees. Omnes is committed to ESG issues and has set up the Omnes Foundation in aid of children’s charities. It is also a signatory to the United Nations Principles for Responsible Investment (PRI). www.omnescapital.com - Press contacts Omnes: Gaëlle de Montoussé, gaelle.demontousse@omnescapital.com - +33 1 80 48 79 16 Brackendale Consulting: Fay Margo, fay@brackendaleconsulting.com - +44 7962115825.  Website : http://www.omnescapital.com

*About SOPRA STERIA:
*Sopra Steria, a European leader in digital transformation, provides one of the most comprehensive portfolios of offerings on the market, spanning consulting, systems integration, industry-specific solutions, infrastructure management and business process services. It provides end to end solutions to address the core business needs of large companies and organisations, helping them remain competitive and grow. Combining added value with innovative high-performance services, Sopra Steria excels in guiding its clients through their transformation projects to help them make the most of digital technology. With nearly 42,000 employees in more than 20 countries, Sopra Steria generated revenue of €3.8 billion in 2017. Sopra Steria (SOP) is listed on Euronext Paris (Compartment A) – ISIN: FR0000050809. For more information, Website: http://www.soprasteria.com

*Sentryo Media Contact :*
Thomas Lovy
*Sentryo*
Thomas.lovy@sentryo.net
+33 (0) 970 726 353

*US Media Contact :*
Barrie Locke
*Ripple Effect Communications*
barrie@rippleeffectpr.com
617-536-8887 Reported by GlobeNewswire 20 minutes ago.

BEIJING, Dec. 3, 2018 /PRNewswire/ -- A news report by China.org.cn on the speech of Zhang Ruimin, the Chairman of the Board and the CEO of the Haier Group at the Global Drucker Forum in Vienna:

Zhang Ruimin, chairman of the Board and CEO of Haier Group, was the only Chinese entrepreneur invited to attend the Global Peter Drucker Forum in Vienna, Austria on Nov. 30, 2018. This is the 2nd time Zhang has been invited to the Drucker Forum, which management expert Charles Handy has referred to as "the birth place of business change."Zhang Ruimin, chairman of the Board and CEO of Haier Group, delivers a speech at the Global Peter Drucker Forum in Vienna on Nov. 30. [Photo courtesy of Haier]

In his speech, titled "Rendanheyi – Maximizing Everyone's Value," Zhang explained how the Rendanheyi Model can disrupt traditional bureaucracy models by implementing an IOT mindset. This is achieved by making changes to people, organization systems and compensation mechanisms, and turning the organization into a Three-Selves organization. In this way, employees are inspired to be innovative and instilled with entrepreneur vitality, bringing about the alignment of employee value and user value. His speech also explained how Zhang Ruimin transformed Haier into an open entrepreneur ecosystem through the innovative Rendanheyi Model, and built a platform where every person has the opportunity to be an entrepreneur, making Peter Drucker's vision of "Every person is his own CEO" a reality.

This year, the forum focuses on the theme of "Management, in People's Dimension" to explore whether leaders in the 21st century should be adept at understanding people-related management techniques just as they do with the latest scientific discoveries. These days, IOT is no longer just a topic of scientists and researchers, but is closely connected to everyone's work and life. Yet, in this trend, most enterprises focus more on technological reform and innovation with little regard for the value of people involved in this process.

Zhang's speech triggered a spirited discussion among experts and entrepreneurs at the forum. Members of the board of directors from Germany's Bosch expressed admiration for the innovation and reform at Haier, commenting that "Haier sets up a model for us to learn." Julia Wang, dean of Drucker School of Management (Hong Kong), said she believes the Rendanheyi Model can be applied not only to business management, but also to other social organizations. Stuart Crainer, author of "The Management Century" and co-founder of Thinkers50, said the successful practices of the model are producing greater impacts on Europe and the world at large. 

In his book "A Business Reformation: Lighting the Flame," Charles Handy pointed out that while the era calls for business reform, people need to reconsider the organization and figure out how to keep integrity of human value within corporations. He said, "This will be a reform, an unpopular reform." Then who will light the flame of this global reform?Zhang Ruimin, chairman of the Board and CEO of Haier Group, is the only Chinese entrepreneur invited to attend the Global Peter Drucker Forum in Vienna, Austria on Nov. 30. [Photo courtesy of Haier]

As a master in integrating eastern and western management thinking, Zhang Ruimin proposed the Rendanheyi Model back in 2005, and started the great transformation of the company for the age of the internet. The rigid hierarchy in the organization was thoroughly destructed, and the company became a networked organization. On Haier's platform, a great number of microenterprises were created, which were self-employed, self-motivated and self-organized. So far, there are over 200 entrepreneur-microenterprises on Haier's platform, among which 23 have been evaluated at over 100 million yuan, and 33 have received financing. Haier's open entrepreneur platform Haichuanghui established 24 incubators in 9 countries, attracting over 3000 registered projects, including 300 incubator projects, with a total evaluation of over 30 billion yuan. 

During his speech, Zhang Ruimin also announced plans for the Vanguard Company alongside world-renowned management expert Gary Hamel. As a witness to and supporter of Haier's reform, Gary Hamel co-authored "The End of Bureaucracy" with Michelle Zanini. The piece served as a cover article for the Harvard Business Review, a leading management publication, and prominently featured Haier's management reform as an example. This time, Gary Hamel will join Haier, the company that he believes to be "the best case study for busting bureaucracy," in launching the Vanguard Company forum, where case studies like Haier's will be researched and studied. The goal of this forum is to inspire great changes in management organization, speed up management innovation, and build an organizational form that fundamentally suits the future of humanity. 

After listening to Zhang Ruimin's speech, the official social media of the European Institute of Business Administration (INSEAD) said that it believed the Rendanheyi Model to be a key management innovation of the 4th Industrial Revolution. The Executive Dean of Education at INSEAD pointed out that the Chinese management model would be studied by western countries as Japanese models had been before. This echoes Charles Handy's comments from earlier. In this way, the Vanguard Company helps serve as fuel for the fire of management change. 

This year the forum was held at the Hofburg Imperial Palace in Vienna. This 700-year-old palace was where Beethoven's Eighth Symphony was played for the first time, and today it is where the horn is sounded for the Global Management Enlightenment Movement. 

View original content to download multimedia:http://www.prnewswire.com/news-releases/zhang-ruimin-lights-the-fire-of-management-change-300758828.html Reported by PR Newswire Asia 14 minutes ago.

Mark Thompson Joins as Chief Operating Officer and Mascha van Eijk as Regional Sales Manager for Infoverity in EMEA

DUBLIN, Ohio and VALENCIA, Spain (PRWEB) December 03, 2018

Infoverity, a leading systems integrator and global provider of Master Data Management (MDM) and Product Information (PIM) strategy and implementation, Next Gen Analytics and Managed Services, today announced the expansion of its global operations with the addition of Mark Thompson as Chief Operating Officer and Mascha van Eijk as Regional Sales Manager for Infoverity in EMEA.

In his role as COO, Mark will focus on strategic growth, operations and leadership development at Infoverity. Prior to Infoverity, Mark was with Aileron, a business advisory firm, where he worked with more than 100 organizations on strategic planning, board governance, business model design, process mapping, and executive coaching. Prior to Aileron, Mark served as CEO for 14 years with LJB Inc., where he led the firm through its most profitable years. Mark holds an MBA from Miami University, and an MS and BS in Civil Engineering from the University of Cincinnati.

Mascha van Eijk joins Infoverity’s EMEA team as the Regional Sales Manager of the EMEA Region which is headquartered in Valencia, Spain. Mascha has many years of international sales and business development experience in Outsourcing, global Managed Services, Telecom, SaaS and Internet of Things (IoT). Together with Infoverity EMEA Director Brian Grant, Mascha will be responsible for further growth of Infoverity in the Region, working closely with Infoverity’s existing teams throughout Europe and Russia.

“The addition of Mark and Mascha represents our ongoing commitment to the strategic development of our company and ability to serve our clients' growing needs,” explained Matt Wienke, Infoverity President. “They each bring deep expertise in their respective roles, and will contribute immediately to our culture of client service and building for the future. We’re very proud to share this news with our clients and business partners in this time of expanding demand for information management business solutions.”

About Infoverity

Founded in 2011, Infoverity is a leading systems integrator and global provider of Master Data Management (MDM), Product Information Management (PIM) strategy and implementation, next generation analytics, managed services and hosting solutions that help large enterprises in the retail, consumer goods, manufacturing, financial and healthcare sectors to simplify and maximize the value of their information. Infoverity is on the Inc. 5000, and is recognized by IDG’s Computerworld as one of the Best Places to Work in IT, as a Wonderful Workplace for Young Professionals and as a Best Place to Work by Business First. Infoverity’s global headquarters is in Dublin, Ohio, the EMEA headquarters is in Valencia, Spain and additional offices are located in the United Kingdom, France, Germany and Russia. For more information on Infoverity solutions, visit Infoverity.com, follow @Infoverity on Twitter, or contact us today. Reported by PRWeb 4 hours ago.

The Central European University (CEU) describes the decision as 'an arbitrary eviction' that violates academic freedom Reported by Independent 4 hours ago.

· *TD Ameritrade on Monday launched a new chatbot for WeChat users who based in the US. *
· *The WeChat chatbot, similar to those on Facebook Messenger and Twitter, offers investment information, ranging from global market updates to volume spikes. It does not allow trading over the platform. *
· *The discount brokerage is trying to court more Asian investors. *

--------------------

Discount broker TD Ameritrade unveiled a chatbot for users of popular Chinese messaging app WeChat living in the US. It's the latest attempt by the discount brokerage to tap further into the massive user base of the largest social network in China.

TD had rolled out an initial partnership with WeChat in August, but made the service accessible only to investors in  Hong Kong. The new launch allows the firm to offer the same services to WeChat users living in the US, a clientele it inherited from its $4 billion acquisition of Scottrade in 2017.

“When we did our acquisition of Scottrade, as part of that acquisition, we on-boarded a very robust and engaged client book of Asia Pacific clients in the U.S.,” said Sunayna Tuteja, director of innovation and strategic partnership at TD Ameritrade. “They're very engaged on WeChat." 

The firm’s WeChat chatbot, similar to those it built via Facebook Messenger and Twitter, provides users with investment information, including market updates, company news, trading quotes, or volume spikes, though users can't trade on the platform.

*Read more:* 'Alexa, buy 10 shares of Facebook': A discount brokerage giant now lets Main Street investors trade stocks via voice

The partnership with WeChat comes at a time when when TD Ameritrade is trying to grow its business in Asia. Earlier this year, TD Ameritrade opened a new office in Hong Kong and unveiled the “ThinkorSwim”platform to offer trading in stocks, options, and futures listed in the U.S. exchanges. In August, it rolled out an AI-powered chatbot for investors in Singapore, allowing them to trade via Facebook Messenger.

TD is aiming to enter into the mainland China market next, said Tuteja. 

“We just want to be very deliberate and purposeful, so we are taking at some time to really learn and understand how we would structure that entry,” she added.

Founded by Tencent in 2011, WeChat is a fast-growing social and messaging platform in Asia. It dominates the Chinese market, but has also gained in popularity in other regions, like Southeast Asia, Europe, and the US. As of February, WeChat has hit 1 billion monthly active users across the globe, according to “Pony” Ma Huateng, Tencent's co-founder and chief executive officer.

· Read more:
· China is minting a billionaire every 3 days as the tech boom unlocks 'stealth wealth'

· TD Ameritrade just made a move to become a one-stop shop for wealthy investors — and it highlights a hot trend on Wall Street

·  

Join the conversation about this story »

NOW WATCH: 7 places you can't find on Google Maps Reported by Business Insider 4 hours ago.

European markets got off to a good start on Monday and sharply higher on Monday, following the global-relief in Asia rally after the U.S. and China trade negotiating teams had warm talks on Saturday night over dinner in Argentina's G20 summit where they manage to agree to take steps to ease trade tensions. We saw the Stoxx Europe 600 index jump 1.9% to 364.23, with the highest proportion of those gains coming from Germany where the DAX rallied over 2.6% to 11,547.07. The FTSE 100 index added up  2% to 7,116.97 while Frances CAC 40 index climbed close to 2% to 5,104.70. 

Washington and Beijing have now agreed to postpone the proposed increases of further tariffs on China in a reciprocal deal where China have pledged to buy more U.S. products - This sent shares in trade-sensitive sectors, such as autos and resources stocks that saw the most significant gains, higher. The main benefactors early in the day were with Volkswagen AG rallying 4% and Rio Tinto PLC jumping nearly 5%. Oil majors were also contributing to European indexes as the price of crude oil rallied almost 5% in early European markets sending BP PLC 2% higher.

However, during the day, we had a median reversion effect in the indexes as the hysteria died down somewhat leaving the provisional and come 'confirmed' closing levels as follows:

· Stoxx Europe 600 index to close at 360.40
· German DAX, +1.9% higher - 'Confirmed' 1.85% higher
· France's CAC, +1.1% higher
· UK's FTSE, +1.4% higher  - 'Confirmed' 1.18% higher

And as for oil, WTI is up around 2.5% at $52.56 at the time of writing. 

*DAX technical analyses:*

From a technical perspective, the DAX remains bullish-neutral although that break above the 21-D SMA, in the absence of any further mean reversion to close the bullish gap, bulls can target the 50-D SMA and confluence of the 23.6% Fibo target at 11617. RSI was capped at 70 on the 4-hr time frame while daily turns higher. Should price close the gap, as is often the case, the 21-D SMA will need to give way at 11369 first. Deeper territory below 11207 as the recent lows would open up the 11007 level as the 19th Nov low. 10860 comes as the 2016 Aug-Nov level as the critical downside target.

Support levels: 11238 11159  11111.

Resistance levels: 11365 11413 11492

*FTSE technical analyses:*

From a technical perspective, the index has breached the 23.6% target at 7091 and pierced the 50-D SMA at 7127, scoring a high of 7146.93 - This leaves the price above the descending resistance line as the index moves sideways out of the channel formed between the September swing low and high building the starting points for descending support and resistance. Bulls can pursue the upside so long as the 21-D SMA that guards the gap holds; this is located at 7045 and price closes at 7062. The important next upside target is the 38.2% Fibo of 2018's range at 7244. 

Support levels: 6962 6919 6879

Resistance levels: 7046 7086 7130 Reported by FXstreet.com 4 hours ago.

· *"PUBG Mobile" has been named Google Play's Best Game of 2018 and Fan Favorite Game of 2018.*
· *"PlayerUnknown's Battlegrounds" is a battle-royale shooter and helped inspire "Fortnite: Battle Royale" and the Blackout mode in "Call of Duty: Black Ops 4."*
· "PUBG Mobile" is free on Google Play, while the versions on Xbox One, PlayStation 4, and PC are $29.99.

Google Play has released its Best of 2018 list, and battle-royale shooter "PUBG Mobile" tops the list as both Best Game and Fan Favorite Game.

As the name suggests, "PUBG Mobile" is the mobile version of "PlayerUnknown's Battlegrounds," the PC game that's largely credited with inspiring the battle royale genre leading to "Fortnite: Battle Royale" and copycat game modes in "Call of Duty: Black Ops 4" and "Battlefield V."

Hundreds of millions of players around the world are playing battle royale games on video game consoles and smartphone alike. It helps that the two biggest games in the genre, "PUBG" and "Fortnite," are free on mobile devices. Research firm SensorTower reports that "PUBG Mobile" has been downloaded more than 240 million times and has earned more than $113 million through microtransactions.

"PUBG Mobile" and the console and PC versions of "PlayerUnknown's Battlegrounds" have separate player bases, but the games function the same. "PUBG" throws 100 players onto an island with scattered resources. Once the game starts, they need to find weapons and items to defend themselves with as the safe areas of the island begin to shrink. The last player or team surviving at the end of the round is the winner. --------------------

*Read more:* It looks like the smash-hit game that paved the way for 'Fortnite: Battle Royale' is finally coming to PlayStation 4

--------------------

While "Fortnite" is more popular than "PUBG" overall, the game is not downloadable in the Google Play Store — Android users must instead install the game directly from the Fornite website — clearing the way for "PUBG Mobile" to dominate on Android devices and Google Play download rankings. "Fortnite" is also unavailable in China, the world's largest video game market, due to the Chinese government's ongoing freeze on new game releases.

Both the PC version of "PlayerUnknown's Battlegrounds" and "PUBG Mobile" were published in China by Tencent prior to the government's call for increased video game regulation. The game has seen tens of millions of downloads in China but Tencent is still not allowed to monetize "PUBG Mobile" in China with in-game purchases.

While "Fortnite" still reigns as the world's most popular game, the global reach of "PlayerUnknown's Battlegrounds" will help ensure that its around for years to come. The console version of "PlayerUnknown Battlegrounds" recently celebrated the one-year anniversary of its launch on Xbox One, and will be released on PlayStation 4 on December 7th. The game's creators have also revealed plans for "PUBG" esports leagues in North America and Europe starting in 2019.

*SEE ALSO: It looks like the smash-hit game that paved the way for 'Fortnite: Battle Royale' is finally coming to PlayStation 4*

*SEE ALSO: The new 'Call of Duty' has a surprisingly fantastic Battle Royale mode aimed directly at 'Fortnite'*

Join the conversation about this story »

NOW WATCH: Why autocorrect makes so many mistakes, according to the former Apple engineer who helped create it Reported by Business Insider 4 hours ago.

**

· *Internal documents seen by Business Insider reveal that Tesla had plans to build its next new vehicle, the Model Y SUV crossover, at its Nevada Gigafactory and its yet-to-be-built factory in China. *
· *According to the documents, which were sent before the company's earnings call in October, the company had planned to ramp both factory's Model Y production lines up to 7,000 and 5,000 cars, respectively, by early 2021.*
· *The Model Y, which will be built on the Model 3 platform, was slated to have a third row of seats, an IP Riser, and a center consul riser, according to the documents. *
· *A Tesla spokesperson told Business Insider that the timeline and information in the documents were "outdated," but did not specify any further.*

Internal documents given to Tesla employees a few weeks before the company's October earnings release reveal the company had plans to manufacture its next car, the Model Y SUV, at a rapid speed.

According to the document, Tesla planned a production ramp of 7,000 Model SUVs a week at its Gigafactory 1 in Nevada by December 20, 2020 and 5,000 Model Ys a week at its China Gigafactory by February 2021.

Other details in the Model Y documents include: 

· The company planned to have a pilot Model Y line built at Gigafactory 1 by June 1, 2020, with standard operating procedures in place by August 1, 2020. By September 1, 2020, the company aimed to ramp production up to 2,000 Model Ys a week at Gigafactory 1. 
· The China Model Y pilot line was projected to be built by early October 2020 with the line ramping up to 2,000 Model Ys by November/December 2020.
· The Model Y, like any crossover vehicle, is built on a car's platform. In this case, that car is the Model 3, so to build the Model Y Tesla is simply making some additions and changes to the Model 3 line.
· The Model Y documents reviewed by Business Insider outline manufacturing/design changes or additions to the vehicle that will make it different than the Model 3. They include the addition of an IP Riser, a center console riser, and third row of seats.

Business Insider sent an email to Tesla including these details as well as a series of questions about these projections and whether or not they may be used in a pitch to raise capital for the company.

In response, a Tesla spokesperson said that the details in the documents were no longer accurate. 

"The timelines and information shared here are outdated. When we have details to announce, we will certainly share them. In the meantime, we remain focused on Model 3, which we are excited to bring to Europe and China early next year," the spokesperson said. 

*Read more:* 70-hour weeks and 'WTF' emails: 42 employees reveal the frenzy of working at Tesla under the 'cult' of Elon Musk

The company did not respond to follow-up questions asking to clarify when these dates were set as goals, or whether or not the general goal to manufacture the Model Y in 2020 — which CEO Elon Musk discussed on the company's third quarter conference call — remained.

"It does seem like these timelines are quite aggressive based on what Tesla has achieved in the past," said Rebecca Lindland, an executive analyst at Kelly Blue Book. "There was a lot of fanfare when the company hit 5,000 Model 3s a week over the summer. With this schedule, they're looking at 7,000 Model Ys a week [at the Nevada factory] by 2020 and that just seems very high." 

In the past, Tesla has struggled with launching new models as smoothly as traditional automakers. In an interview with Axios on HBO, CEO Elon Musk said that the ramp of the company's most recent model, the Model 3, took the company "single digit weeks" away from bankruptcy this year.

"Essentially the company was bleeding money like crazy and if we didn't solve these problems in a very short period of time we would die," Musk said.

It's not clear how the timeline might have changed. But auto industry experts told Business Insider that the original schedule may have presented its own particular set of challenges. For starters, new car launches often take three to five years to execute, not two. What's more, Tesla would have to grapple with building a new factory in China before manufacturing the car there.

A former employee told Business Insider that these documents were given to engineers to signal the end of their work on the Model 3 line, and the beginning of their work on the Model Y.

If you are a Tesla employee or customer who has a story to share about a car or experience with the company, give me a shout at llopez@businessinsider.com.

** A Tesla ramp (with Chinese characteristics) **

The Model Y is being built largely based on plans for the Model 3. In the auto business, they call that putting "a top hat" on an existing model. That should make the process simpler than launching an entirely new vehicle.

That said, industry experts told Business Insider that even with this simplification, Tesla is still likely to face challenges as it ramps up production of the new SUV. 

Tesla still needs to build out space for the Model Y at its Nevada factory. It also still has yet to build, tool, and train the workers in its factory in China. Once that's done, they will still need to hire and train staff overseas.

"China is notorious for turnover," Lindland said. "They're going to face higher levels of turnover than in the states and there are cultural differences to account for."

One current Tesla employee, who asked for anonymity, said he was worried the company isn't learning from its previous mistakes. Instead, he said, the company is exporting them. 

A former engineer who was familiar with the company's Model Y plans also said the company's expansion to China could present issues. 

"It [the Model Y manufacturing plan] looks like copying and pasting what they've done at Fremont ... but now they're facing a new problem, working from China," one former Tesla engineer told Business Insider. 

"I think that the main flaw is he [Elon Musk] thinks the system at Fremont can be replicated and that that replication is the best way to spend capital, which it's not. The system in Fremont could use some upgrading in terms of lessons learned ... What I could imply from looking at [these documents] is that they're not going to apply those lessons."

As an example, the engineer pointed out that currently, Fremont's production line doesn't have buffer space for cars. So if something goes wrong at the end of the line, the entire line has to stop because there's no space to move any of the cars ahead. Based on these Model Y plans, the engineer does not think Tesla is going to fix that issue.

If you are a Tesla employee or customer who has a story to share about a car or experience with the company, give me a shout at llopez@businessinsider.com.

*SEE ALSO: Tesla met its goal of making 1,000 Model 3s per day*

Join the conversation about this story »

NOW WATCH: This LEGO Bugatti Chiron is drivable — here's what it can do Reported by Business Insider 4 hours ago.

-  New data on APL-2 demonstrate improvements in hematological parameters in cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA)-  CAD patients treated with APL-2 had an improvement in hemoglobin within weeks and at day 56 had a normalization of mean hemoglobin, reticulocytes, bilirubin and lactate dehydrogenase

-  wAIHA patients on APL-2 with C3 loading had a meaningful improvement in hemoglobin at day 56 along with a normalization of reticulocytes and lactate dehydogenase

CRESTWOOD, Ky. and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in a poster session today at the 60^th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, California.

In the ongoing PLAUDIT study, 12 CAD patients have been enrolled on APL-2 subcutaneous treatment, of which 5 patients have been treated for at least 56 days. Nine patients with wAIHA were enrolled, seven of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA). Five of these C3+ wAIHA patients have been on APL-2 for at least 56 days. 

“CAD and wAIHA are now the third and fourth indications, along with paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA), with high unmet medical need where APL-2 has demonstrated proof of concept,” said Dr. Cedric Francois, MD, PhD, Apellis co-founder and CEO. “These additional data confirm that the unique way APL-2 targets both C3 as well as C5 via the C5 convertase supports its potential across multiple complement-mediated diseases.  We are pleased that APL-2 demonstrates a clinically meaningful benefit in these two challenging diseases that each lack an FDA-approved therapy.”

Data will be presented by Dr. Morie A. Gertz, M.D., MACP, Chair Emeritus Department of Medicine of the Department of Hematology at the Mayo Clinic in Rochester, Minnesota. Professor Gertz is the primary investigator of the PLAUDIT study.

“APL-2 reduces both intravascular and extravascular hemolysis and in this study has shown a meaningful clinical benefit in both CAD and C3+ wAIHA patients. In addition to increasing hemoglobin in both CAD and C3+ wAIHA, treatment with APL-2 has shown reductions in reticulocytes, lactate dehydrogenase and bilirubin in both of these diseases,” noted Dr. Gertz. “Neither of these conditions has an FDA-approved therapy and these patients are in need of an effective treatment. The breadth of activity in these two distinct diseases is impressive. Importantly, APL-2 appears to be safe and well-tolerated in patients with AIHA.”

*Poster Presentation 2: Inhibition of C3 with APL-2 Results in Normalization of Markers of Intravascular and Extravascular Hemolysis in Patients with Autoimmune Hemolytic Anemia (AIHA)*
Session Name: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster III
Date: Monday, December 3, 2018
Presentation Time: 6:00 PM - 8:00 PM
Location: San Diego Convention Center, Hall GH

PLAUDIT is a phase 2, prospective, open-label study to assess the safety, tolerability, preliminary efficacy, pharmacokinetics and pharmacodynamics of multiple doses of APL-2 in patients with AIHA including warm antibody autoimmune hemolytic anemia (wAIHA) and cold agglutinin disease (CAD).

· *Cold Agglutinin Disease (CAD)

*

· Mean Hb for CAD subjects increased from 8.7 g/dL (n=12) at baseline to 12.1 g/dL (n=5) at day 56, a 3.4 g/dL increase. Two subjects have reached day 168 and showed a sustained clinical benefit as represented by a mean Hb of 12.6 g/dL. · Mean absolute reticulocyte count (ARC) for CAD subjects decreased from 137.5 10⁹/L (n=11) at baseline to 46.6 10⁹/L (n=5) at day 56, with sustained clinical benefit as represented by a mean ARC of 70.8 10⁹/L (n=2) at day 168 · Mean bilirubin for CAD subjects decreased from 1.9 mg/dL (n=12) at baseline to 0.5 mg/dL (n=5) at day 56 · Mean LDH for CAD subjects decreased from 487.8 U/L (n=12) at baseline to 173.4 U/L (n=5) at day 56 with sustained benefit as represented by mean LDH of 143.5 U/L (n=2) at day 168
· *C3+ Warm Antibody Autoimmune Hemolytic Anemia (C3+ wAIHA)

*

· Mean Hb for C3+ wAIHA subjects increased from 9.3 g/dL (n=7) at baseline to 11.3 g/dL (n=5) at day 56, a 2.0 g/dL increase.  · Mean absolute reticulocyte count for C3 + wAIHA subjects decreased from 185.5 10⁹/L (n=7) at baseline to 61.1 10⁹/L (n=5) at day 56  · Mean bilirubin for C3+ wAIHA subjects decreased from 0.8 mg/dL (n=7) at baseline to 0.4 mg/dL (n=6) at day 56 · Mean LDH for C3 + wAIHA subjects decreased from 306.9 U/L (n=7)  at baseline to 150.2 U/L (n=5) at day 56

*Cold Agglutinin Disease (CAD)*
Cold Agglutinin Disease (CAD) is a severe, chronic rare autoimmune disorder caused by pathogenic Immunoglobulin M (IgM) antibodies that react with red blood cells at temperatures below 30^oC and leads to agglutination of the red blood cells (RBCs). Agglutinated RBCs activate a part of the body’s immune system called the complement system leading to destruction of the RBC. The disease is often characterized by chronic anemia, severe fatigue, and an increased risk of life-threatening events such as stroke. There are an estimated 10,000 CAD patients across the United States and Europe. There are currently no approved therapies for CAD.

*Warm autoimmune hemolytic anemia (wAIHA)*
Warm autoimmune hemolytic anemia (wAIHA) is a rare autoimmune disorder caused by pathogenic Immunoglobulin G (IgG) antibodies that react with RBC and can activate the complement system leading to the premature destruction of red blood cells at normal body temperature. The disease is often characterized by profound, and potentially life-threatening anemia and other acute complications, including severe and life-threatening hemolysis, severe weakness, enlarged spleen or liver, rapid heart rate, chest pain, heart failure and fainting. There are estimated to be more than 30,000 wAIHA patients across the United States and Europe. C3+ wAIHA has been estimated to represent as much as two thirds of the total wAIHA population.  There are currently no approved treatments for wAIHA.

*About APL-2 *
APL-2 is designed to inhibit the complement cascade centrally at C3 and may have the potential to treat a wide range of complement-mediated diseases more effectively than is possible with partial inhibitors of complement. APL-2 is a synthetic cyclic peptide conjugated to a polyethylene glycol (PEG) polymer that binds specifically to C3 and C3b, effectively blocking all three pathways of complement activation (classical, lectin, and alternative). To date, APL-2 has generally been well-tolerated. No significant infections have been observed in trials involving the systemic administration of APL-2, including the trials in PNH, AIHA or other trials. 

*Clinical trials *
Specifically in hematologic diseases, Apellis is currently evaluating APL-2 in a Phase 2 clinical trial in autoimmune hemolytic anemia (AIHA) and a Phase 2 clinical trial in complement dependent nephropathies, as well as two Phase 1b trials (PHAROAH and PADDOCK) for systemic administration in paroxysmal nocturnal hemoglobinuria (PNH). Previously reported interim data from these trials showed improvements in lactate dehydrogenase and hemoglobin levels in patients who are suboptimal responders to eculizumab and untreated patients, respectively. The company is also conducting a Phase 3 trial for patients with PNH. For additional information regarding our clinical trials, please visit www.apellis.com/clinical-trials.html.

*About Apellis**
*Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. For additional information about Apellis and APL-2, please visit http://www.apellis.com.

*Forward-Looking Statements  *
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials such as the results reported in this release will be indicative of results that will be generated in future clinical trials; whether APL-2 will successfully advance through the clinical trial process on a timely basis, or at all; whether the results of such clinical trials will warrant regulatory submissions and whether APL-2 will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies for GA, PNH or any other indication; whether, if Apellis’ products receive approval, they will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2018 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

*Media Contact:**
*Nicole Clifford
nclifford@denterlein.com  
617.482.0042  (office)
949.533.9295  (mobile)

*Investor Contact:**
*Alex Kane 
akane@w2ogroup.com
212.301.7218  (office)
929.400.2691  (mobile)  Reported by GlobeNewswire 4 hours ago.

*Human Fibrinogen Concentrate Market (Type: 0.5g, 1.0g, Others; Application: Congenital Fibrinogen Deficiency, Surgical Procedures) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2025*LOS ANGELES, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “*Human Fibrinogen Concentrate Market* (Type: 0.5g, 1.0g, Others; Application: Congenital Fibrinogen Deficiency, Surgical Procedures) – Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2025”, estimates that global human fibrinogen concentrate market is expected to reach the market value of around $1.4 billion by 2025 and is projected to grow at a CAGR of around 5.8% in terms of revenue during the period 2018 – 2025.

*Download Sample Pages@ https://www.acumenresearchandconsulting.com/request-sample/903 *

The market will be driven by growing events where fibrinogen tests are encouraged, namely, consolidate stroke, liver ailments, hemophilia, flammable illnesses, and others. As demonstrated by National Hemophilia Foundation, New York, U.S., factor I deficiency, which fuses afibrinogenemia, dysfibrinogenemia, or hypofibrinogenemia has visible occurrence in 2 individuals for every million in the U.S. On the other hand, liver threatening development also assembles the risk of hemostasis, as it conveys a huge part of coagulating segments and inhibitors. Furthermore, it similarly makes diverse proteins related with fibrinolysis. In 2012, it has been assessed that around 120,000 people were encountering liver threat and unsurprising to rise exponentially. This exponential development of liver malady will in turn expand the market growth of human fibrinogen concentrate market globally. Notwithstanding, certain antagonistic responses to be specific as dyspnea, blood vessel thrombosis, regurgitating, chills, queasiness, and pneumonic embolism hamper the market development. Diagnostics industry is driven by a noteworthy suppliers and traders over the globe. This has helped in tremendous market infiltration of fibrinogen tests, especially in small and rising economies where the prevalence of couple of afflictions, for example, are threatening the development. The fibrinogen test is anticipated to lessen up cost in the light of making development, and extending opportunities which ultimately act as a boosting aspect for human fibrinogen concentrate market in near future.

Although factor I is documented for its mechanisms concerned in each primary and secondary homeostasis, its function area is way more extensive. So far, human factor I level has been rumored to be related to several factors, together with patient characteristics like sex, age and BMI, similarly as indicators like cancer presence, surgical intumescence, large hemorrhage, intromission, plasma transfusion, and administration of hemocoagulase [7–17]. The current study analyzed attainable predictors of plasma factor I level to spot risk factors for surgical factor I deficiency which could curb the growth of the market. 

*View Full Report@ https://www.acumenresearchandconsulting.com/human-fibrinogen-concentrate-market *

*Regional Analysis*

The study by Acumen Research shows that North America, most noticeably the United States, held the prime position in human fibrinogen concentrate market in 2017, followed by the Europe which is slightly behind NA in terms of volume and value. China, India, and Japan additionally hold a conspicuous share and are relied upon to proceed with its development through the determining time range. Southeast Asia is foreseen to quicken its pace over the coming time because of more technological progression in rising economies. Additionally, emerged economies comprise of latest diagnostics machines which is a significant aspect that they will keep on administering the market all through the assessed years.

*Insights on Market Segments*

 Global human fibrinogen concentrate market is segmented by type, application and geography. Based on different types, the market is segmented into 0.5g, 1.0g, and other. Also, application is further bifurcated into congenital fibrinogen deficiency and surgical procedures. Based on geography market is further classified into North America, Europe, China, India, Japan, Southeast Asia, ROW.  

*Congenital Fibrinogen Deficiency Held Largest Share In Human Market in 2017*

Congenital fibrinogen deficiency segment held the most notable share in human fibrinogen market in 2017, owing to the factors such as occurrences of afibrinogenemia which at present is 1 in a million. Hypo-and dysfibrinogenemia are most probably found in both genders and are more consecutive. Moreover, in any age, fibrinogen deficiency can be detected but youths are more prone to these diseases consistently in the neonatal period. Due to the use of fibrinogen in treatment of hemorrhages it is always recommended utilizing toughened plasma if fibrinogen is not available. Routine prophylaxis is exercise to disenchant in case of premature births if fibrinogen detected in early phase in pregnancy. Consequently, holding the prime piece of the overall industry and is foreseen to keep up its predominance over the forecasting period.

*Key Players*

The market is focused with various principle players working in comparable geographies, with modest item separation. Moreover the foreign players need to fight with domestic players who offer practically identical things at more affordable rates. The domestic players furthermore approach a strong dissemination channel which causes them compete with global players.

Some of the important players operating in the global human fibrinogen concentrate market, profiled in the report include, LFB Group, Shanghai RAAS, CSL Behring, Greencross, Hualan Biological Engineering, Shanghai RAAS, Harbin Pacific Biopharmaceutical, Shanghai XinXing Medical, Boya among others.

Besides, Human fibrinogen concentrate, produced by CSL Behring, is a very purified, lyophilized fibrinogen (coagulation factor I) powder produced from human plasma.

*Inquiry Before Buying - **https://www.acumenresearchandconsulting.com/inquiry-before-buying/903*

*Table of Content*

*Chapter 1.  Industry Overview of Human Fibrinogen Concentrate*

1.1  Definition and Specifications of Human Fibrinogen Concentrate
1.1.1  Definition of Human Fibrinogen Concentrate
1.1.2  Specifications of Human Fibrinogen Concentrate
1.2  Human Fibrinogen Concentrate Segment by Types
1.2.1  Global Human Fibrinogen Concentrate Production and Growth Rate Comparison by Types (2013-2025)
1.2.2  Global Human Fibrinogen Concentrate Production Market Share by Types in 2017
1.2.3  0.5g
1.2.4  1.0g
1.2.5  1.5g
1.2.6  2.0g
1.3  Global Human Fibrinogen Concentrate Segment by Applications
1.3.1  Global Human Fibrinogen Concentrate Consumption Comparison by Applications (2013-2025)
1.3.2  Congenital Fibrinogen Deficiency
1.3.3  Surgical Procedures
1.4  Global Human Fibrinogen Concentrate Market by Regions
1.4.1  Global Human Fibrinogen Concentrate Market Size and Growth Rate Comparison by Regions (2013-2025)
1.4.2  North America Human Fibrinogen Concentrate Status and Prospect (2013-2025)
1.4.3  China Human Fibrinogen Concentrate Status and Prospect (2013-2025)
1.4.4  Europe Human Fibrinogen Concentrate Status and Prospect (2013-2025)
1.4.5  Japan Human Fibrinogen Concentrate Status and Prospect (2013-2025)
1.4.6  India Human Fibrinogen Concentrate Status and Prospect (2013-2025)
1.4.7  Southeast Asia Human Fibrinogen Concentrate Status and Prospect (2013-2025)
1.5  Global Human Fibrinogen Concentrate Market Size
1.5.1  Global Human Fibrinogen Concentrate Revenue Status and Outlook (2013-2025)
1.5.2  Global Human Fibrinogen Concentrate Capacity, Production Status and Outlook (2013-2025)

*Chapter 2.  Manufacturing Cost Structure Analysis of Human Fibrinogen Concentrate*

2.1  Raw Material and Suppliers
2.1.1  Manufacturing Cost Structure Analysis of Human Fibrinogen Concentrate
2.1.2  Raw Materials
2.1.2.1  Labor Cost
2.1.3  Manufacturing Expenses
2.2  Manufacturing Process Analysis of Human Fibrinogen Concentrate
2.3  Industry Chain Structure of Human Fibrinogen Concentrate

*Chapter 3.  Technical Data and Manufacturing Plants Analysis of Human Fibrinogen Concentrate*

3.1  Capacity and Commercial Production Date of Global Human Fibrinogen Concentrate Major Manufacturers in 2017
3.2  Manufacturing Plants Distribution of Global Human Fibrinogen Concentrate Major Manufacturers in 2017
3.3  R&D Status and Technology Source of Global Human Fibrinogen Concentrate Major Manufacturers in 2017
3.4  Raw Materials Sources Analysis of Global Human Fibrinogen Concentrate Major Manufacturers in 2017

*Chapter 4.  Global Human Fibrinogen Concentrate Overall Market*

4.1  2013-2018E Overall Market Analysis
4.2  Capacity Analysis
4.2.1  2013-2018E Global Human Fibrinogen Concentrate Capacity and Growth Rate Analysis
4.2.2  2017 Human Fibrinogen Concentrate Capacity Analysis (Company Segment)
4.3  Sales Analysis
4.3.1  2013-2018E Global Human Fibrinogen Concentrate Sales and Growth Rate Analysis
4.3.2  2017 Human Fibrinogen Concentrate Sales Analysis (Company Segment)
4.4  Sales Price Analysis
4.4.1  2013-2018E Global Human Fibrinogen Concentrate Sales Price
4.4.2  2017 Human Fibrinogen Concentrate Sales Price Analysis (Company Segment)

*Chapter 5.  Human Fibrinogen Concentrate Regional Market Analysis*

5.1  North America Human Fibrinogen Concentrate Market Analysis
5.1.1  North America Human Fibrinogen Concentrate Market Overview
5.1.2  North America 2013-2018E Human Fibrinogen Concentrate Local Supply, Import, Export, Local Consumption Analysis
5.1.3  North America 2013-2018E Human Fibrinogen Concentrate Sales Price Analysis
5.1.4  North America 2017 Human Fibrinogen Concentrate Market Share Analysis
5.2  China Human Fibrinogen Concentrate Market Analysis
5.2.1  China Human Fibrinogen Concentrate Market Overview
5.2.2  China 2013-2018E Human Fibrinogen Concentrate Local Supply, Import, Export, Local Consumption Analysis
5.2.3  China 2013-2018E Human Fibrinogen Concentrate Sales Price Analysis
5.2.4  China 2017 Human Fibrinogen Concentrate Market Share Analysis
5.3  Europe Human Fibrinogen Concentrate Market Analysis
5.3.1  Europe Human Fibrinogen Concentrate Market Overview
5.3.2  Europe 2013-2018E Human Fibrinogen Concentrate Local Supply, Import, Export, Local Consumption Analysis
5.3.3  Europe 2013-2018E Human Fibrinogen Concentrate Sales Price Analysis
5.3.4  Europe 2017 Human Fibrinogen Concentrate Market Share Analysis
5.4  Southeast Asia Human Fibrinogen Concentrate Market Analysis
5.4.1  Southeast Asia Human Fibrinogen Concentrate Market Overview
5.4.2  Southeast Asia 2013-2018E Human Fibrinogen Concentrate Local Supply, Import, Export, Local Consumption Analysis
5.4.3  Southeast Asia 2013-2018E Human Fibrinogen Concentrate Sales Price Analysis
5.4.4  Southeast Asia 2017 Human Fibrinogen Concentrate Market Share Analysis
5.5  Japan Human Fibrinogen Concentrate Market Analysis
5.5.1  Japan Human Fibrinogen Concentrate Market Overview
5.5.2  Japan 2013-2018E Human Fibrinogen Concentrate Local Supply, Import, Export, Local Consumption Analysis
5.5.3  Japan 2013-2018E Human Fibrinogen Concentrate Sales Price Analysis
5.5.4  Japan 2017 Human Fibrinogen Concentrate Market Share Analysis
5.6  India Human Fibrinogen Concentrate Market Analysis
5.6.1  India Human Fibrinogen Concentrate Market Overview
5.6.2  India 2013-2018E Human Fibrinogen Concentrate Local Supply, Import, Export, Local Consumption Analysis
5.6.3  India 2013-2018E Human Fibrinogen Concentrate Sales Price Analysis
5.6.4  India 2017 Human Fibrinogen Concentrate Market Share Analysis

*Chapter 6.  Global 2013-2018Human Fibrinogen Concentrate Segment Market Analysis (by Type)*

6.1  Global 2013-2018E Human Fibrinogen Concentrate Sales by Type
6.2  Different Types Human Fibrinogen Concentrate Product Interview Price Analysis
6.3  Different Types Human Fibrinogen Concentrate Product Driving Factors Analysis
6.3.1  0.5gHuman Fibrinogen Concentrate Growth Driving Factor Analysis
6.3.1.1.1  Driving Factors-
6.3.2  1.0gHuman Fibrinogen Concentrate Growth Driving Factor Analysis
6.3.2.1.1  Driving Factors-
6.3.3  Other Human Fibrinogen Concentrate Growth Driving Factor Analysis
6.3.3.1.1  Driving Factors-

*Chapter 7.  Global 2013-2018E Human Fibrinogen Concentrate Segment Market Analysis (by Application)*

7.1  Global 2013-2018E Human Fibrinogen Concentrate Consumption by Application
7.1.1  Different Application Human Fibrinogen Concentrate Product Interview Price Analysis
7.2  Different Application Human Fibrinogen Concentrate Product Driving Factors Analysis
7.2.1  Congenital Fibrinogen Deficiency Human Fibrinogen Concentrate Growth Driving Factor Analysis
7.2.1.1.1  Driving Factors-
7.2.2  Surgical Procedures Human Fibrinogen Concentrate Growth Driving Factor Analysis
7.2.2.1.1  Driving Factors-

*Chapter 8.  Major Manufacturers Analysis of Human Fibrinogen Concentrate*

8.1  CSL Behring
8.1.1  Company Profile
8.1.2  Product Picture and Specifications
8.1.3  CSL Behring 2017 Human Fibrinogen Concentrate Sales, Ex-factory Price(USD/vile), Revenue, Gross Margin Analysis
8.1.4  CSL Behring 2017 Human Fibrinogen Concentrate Business Region Distribution Analysis
8.2  LFB Group
8.2.1  Company Profile
8.2.2  Product Picture and Specifications
8.2.3  LFB Group 2017 Human Fibrinogen Concentrate Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.2.4  LFB Group 2017 Human Fibrinogen Concentrate Business Region Distribution Analysis
8.3  Shanghai RAAS
8.3.1  Company Profile
8.3.2  Product Picture and Specifications
8.3.3  Shanghai RAAS 2017 Human Fibrinogen Concentrate Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.3.4  Shanghai RAAS 2017 Human Fibrinogen Concentrate Business Region Distribution Analysis
8.4  Hualan Biological Engineering
8.4.1  Company Profile
8.4.2  Product Picture and Specifications
8.4.3  Hualan Biological Engineering 2017 Human Fibrinogen Concentrate Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.4.4  Hualan Biological Engineering 2017 Human Fibrinogen Concentrate Business Region Distribution Analysis
8.5  Octapharma AG
8.5.1  Company Profile
8.5.2  Product Picture and Specifications
8.5.3  Octapharma AG 2017 Human Fibrinogen Concentrate Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.5.4  Octapharma AG 2017 Human Fibrinogen Concentrate Business Region Distribution Analysis
8.6  Greencross
8.6.1  Company Profile
8.6.2  Product Picture and Specifications
8.6.3  Greencross 2017 Human Fibrinogen Concentrate Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.6.4  Greencross2017 Human Fibrinogen Concentrate Business Region Distribution Analysis
8.7  Shanghai XinXing Medical
8.7.1  Company Profile
8.7.2  Product Picture and Specifications
8.7.3  Shanghai XinXing Medical 2017 Human Fibrinogen Concentrate Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.7.4  Shanghai XinXing Medical 2017 Human Fibrinogen Concentrate Business Region Distribution Analysis
8.8  Boya
8.8.1  Company Profile
8.8.2  Product Picture and Specifications
8.8.3  Boya 2017 Human Fibrinogen Concentrate Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.8.4  Boya 2017 Human Fibrinogen Concentrate Business Region Distribution Analysis
8.9  Harbin Pacific Biopharmaceutical
8.9.1  Company Profile
8.9.2  Product Picture and Specifications
8.9.3  Harbin Pacific Biopharmaceutical 2017 Human Fibrinogen Concentrate Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.9.4  Harbin Pacific Biopharmaceutical 2017 Human Fibrinogen Concentrate Business Region Distribution Analysis

*Chapter 9.  Development Trend of Analysis of Human Fibrinogen Concentrate Market*

9.1  Global Human Fibrinogen Concentrate Market Trend Analysis
9.1.1  Global 2018-2025Human Fibrinogen Concentrate Market Size (Volume and Value) Forecast
9.1.2  Global 2018-2025Human Fibrinogen Concentrate Sales Price Forecast
9.2  Human Fibrinogen Concentrate Regional Market Trend
9.2.1  North America 2018-2025Human Fibrinogen Concentrate Consumption Forecast
9.2.2  China 2018-2025Human Fibrinogen Concentrate Consumption Forecast
9.2.3  Europe 2018-2025Human Fibrinogen Concentrate Consumption Forecast
9.2.4  Southeast Asia 2018-2025Human Fibrinogen Concentrate Consumption Forecast
9.2.5  Japan 2018-2025Human Fibrinogen Concentrate Consumption Forecast
9.2.6  India 2018-2025Human Fibrinogen Concentrate Consumption Forecast
9.3  Human Fibrinogen Concentrate Market Trend (Product Type)
9.4  Human Fibrinogen Concentrate Market Trend (Application)

*Chapter 10.  Human Fibrinogen Concentrate Marketing Type Analysis*

10.1  Human Fibrinogen Concentrate Regional Marketing Type Analysis
10.1.1  Marketing Channel
10.1.2  Direct Marketing
10.1.3  Indirect Marketing
10.1.4  Marketing Channel Development Trend
10.1.5  Market Positioning
10.1.6  Pricing Strategy
10.1.7  Brand Strategy
10.2  Human Fibrinogen Concentrate International Trade Type Analysis
10.3  Traders or Distributors with Contact Information of Human Fibrinogen Concentrate by Regions
10.4  Human Fibrinogen Concentrate Supply Chain Analysis
10.4.1  Raw material suppliers
10.4.2  Human fibrinogen concentrates manufacturers
10.4.3  Distribution channel
10.4.4  End-use industries

*Chapter 11.  Consumers Analysis of Human Fibrinogen Concentrate*

11.1  Consumer 1 Analysis

*Chapter 12.  Conclusion of the Global Human Fibrinogen Concentrate Market Professional Survey Report 2016*

*Chapter 13.  Methodology and Data Source*

13.1  Methodology/Research Approach
13.1.1  Research Programs/Design
13.1.2  Market Size Estimation
13.1.3  Market Breakdown and Data Triangulation
13.2  Data Source
13.2.1  Secondary Sources
13.2.2  Primary Sources
13.3  Disclaimer

*The report is readily available and can be dispatched immediately after payment confirmation.*

*Buy this premium research report - **https://www.acumenresearchandconsulting.com/buy-now/0/903* 

*Would like to place an order or any question, please feel free to contact at **sales@acumenresearchandconsulting.com** | +1 407 915 4157*

*Blog: **http://trendsdesk.com/* Reported by GlobeNewswire 3 hours ago.

Company to Host Investor Meeting and Webcast Today, December 3, at 8 pm PST

BEIJING, China and CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the presentation of clinical data from the pivotal Phase 2 trial of its investigational anti-PD-1 antibody, tislelizumab, in Chinese patients with relapsed/refractory (R/R) classical Hodgkin’s lymphoma (cHL). These data were presented in an oral session at the 60th Annual Meeting of the American Society of Hematology (ASH), taking place December 1-4, 2018 in San Diego, CA, and are included in BeiGene’s new drug application (NDA) in China for tislelizumab for the treatment of patients with R/R cHL.“We set out to address the needs of patients with R/R cHL who have failed to achieve a response or progressed after autologous stem cell transplant (ASCT), or who are not candidates for ASCT, as these patients, unfortunately, have very poor outcomes,” said Jane Huang, M.D., Chief Medical Officer, Hematology, at BeiGene. “We are excited to report strong results including high complete response (CR) rates from the first registration study for this potentially differentiated anti-PD-1 agent.”  

Tislelizumab was discovered by BeiGene scientists, and is being developed globally and in China as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid and hematologic cancers with 11 Phase 3 or potentially registration-enabling studies ongoing or planned to initiate in the near term. The NDA for tislelizumab in China in patients with R/R cHL has been accepted by the China National Medical Products Administration (NMPA, formerly known as CFDA) and granted priority review status.

“In this study, tislelizumab demonstrated an overall response rate (ORR) of 86 percent, including a CR rate of 61 percent. Tislelizumab was also generally well-tolerated by patients with R/R cHL. We are excited by its clinical activity and believe that tislelizumab represents a potential new immunotherapy option for patients in China and elsewhere in the world,” said Yuqin Song, M.D., Ph.D., Associate Professor of Medical Oncology, Deputy Director of the Lymphoma Department at Peking University Cancer Hospital in China, and the presenting author of the study.

*Summary of Clinical Results*

This single arm, open-label, multi-center, pivotal Phase 2 trial of tislelizumab as a monotherapy in Chinese patients with R/R cHL (ClinicalTrials.gov Identifier: NCT03209973) enrolled 70 patients who failed to achieve a response or progressed after ASCT, or received at least 2 prior lines of systemic therapy for cHL and were not an ASCT candidate. Patients were treated with tislelizumab, dosed at 200 mg intravenously every three weeks. The primary endpoint of the trial is ORR assessed by independent review committee (IRC) using PET-based imaging according to the Lugano Classification 2014.

As of May 25, 2018, 70 patients with R/R cHL were evaluable for efficacy and 53 patients (75.7%) remained on study treatment. Thirteen patients received prior ASCT, and the remaining 57 patients were ineligible for prior ASCT, including 53 for failure to achieve an objective response to salvage chemotherapy, two for inadequate stem cell collection or unable to collect stem cells, and two for co-morbidities. The patients had a median of three prior lines of systemic therapy with a range of 2 to 11. The median study follow-up was 7.85 months (3.4-12.7). Results included:

· The ORR by IRC was 85.7 percent (60/70); the CR rate was 61.4 percent (43/70) and the partial response (PR) rate was 24.4 percent (17/70). Among patients who had received prior ASCT, 92.3 percent (12/13) achieved an objective response, with nine patients (69.2%) achieving a CR;  
 
· The median duration of response (DOR) had not yet been reached. The estimated event-free rates at 9 months were 84 percent;
 
· Progression-free survival (PFS) data were preliminary and 6-month PFS was estimated at 80 percent. The median PFS had not yet been reached;
 
· The majority of adverse events (AEs) were grade 1 or 2 in severity. The most frequently reported treatment emergent adverse events (TEAEs) of any grade were pyrexia (52.9%), hypothyroidism (30.0%), weight increased (28.6%), upper respiratory tract infection (27.1%), cough (17.1%), white blood cell count decreased (14.3%), and pruritus (14.3%);
 
· Grade ≥3 TEAEs occurred in 21.4% of patients. The most frequently reported Grade 3 or higher TEAEs were upper respiratory tract infection (2.9%), pneumonitis (2.9%), and productive cough (2.9%);
 
· Four patients (5.7%) discontinued study drug due to TEAEs, including pneumonitis (n=2), focal segmental glomerulosclerosis (n=1), and organizing pneumonia (n=1); there were no cases of TEAE leading to death; and
 
· Immune-related AEs reported in more than five percent of patients included thyroid disorder (18.6%), pneumonitis (5.7%), and skin adverse reactions (5.7%).

*Investor Webcast:
*Date and Time: Monday, December 3, 2018 at 20:00 PST (Tuesday, December 4 at 12:00 China Standard Time)
Webcast:  A live webcast and replay of the event will be available on BeiGene’s investor website, http://ir.beigene.com. 

*About Classical Hodgkin’s Lymphoma*
Hodgkin’s lymphoma is one of the two major types of lymphoma that begin in the lymph nodes and tissues of the lymphatic system. All other lymphomas are classified as non-Hodgkin’s lymphomas. Classical Hodgkin’s lymphoma, the most common form representing about 95 percent of the patients with Hodgkin’s lymphoma, is characterized by the presence of very large cells called Reed-Sternberg cells. There were approximately 2,100 diagnosed cases of Hodgkin’s lymphoma in China in 2012.^i Although the cancer can occur in both children and adults, it is most commonly diagnosed in young adults between the ages of 15 and 35 and in older adults over age 50.

*About Tislelizumab*
Tislelizumab (BGB-A317) is an investigational humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.

Discovered by BeiGene scientists, tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. The new drug application (NDA) for tislelizumab in China for patients with R/R cHL has been accepted by the China National Medical Products Administration (NMPA, formerly known as CFDA) and granted priority review status. BeiGene and Celgene Corporation have a global strategic collaboration for the development of tislelizumab in solid tumors in the United States, Europe, Japan and the rest of world outside Asia.

*About BeiGene*

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,700 employees in China, the United States, Australia and Switzerland, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE^® (nanoparticle albumin–bound paclitaxel), REVLIMID^® (lenalidomide), and VIDAZA^® (azacitidine) in China under a license from Celgene Corporation.^ii 

*Forward-Looking Statements*

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the encouraging clinical data from clinical trials of tislelizumab and BeiGene’s advancement of, and anticipated clinical development, regulatory milestones and commercialization of tislelizumab. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

*Investor Contact*   *Media Contact*
Craig West    Liza Heapes
+1 857-302-5189   + 1 857-302-5663
ir@beigene.com   media@beigene.com

^ihttp://globocan.iarc.fr/Pages/fact_sheets_population.aspx
^ii ABRAXANE^®, REVLIMID^®, and VIDAZA^® are registered trademarks of Celgene Corporation. Reported by GlobeNewswire 2 hours ago.

Diversified Communications announced today the addition of Digital Construction Week to their building, construction and technology portfolio of events. Digital Construction Week is the United Kingdom’s leading trade show dedicated to digital construction, engineering, design, manufacturing, and operation.

PORTLAND, Maine (PRWEB) December 03, 2018

Diversified Communications announced today the addition of Digital Construction Week to their building, construction and technology portfolio of events. Digital Construction Week is the United Kingdom’s leading trade show dedicated to digital construction, engineering, design, manufacturing, and operation.

This event complements Diversified’s industry leading event portfolio with market reach across four countries. Events include GEO Business in London, Commercial UAV Expo Europe in Amsterdam, DesignBUILD in Sydney, and in the United States: AEC Next Technology Expo & Conference and SPAR 3D in Anaheim, CA; International LiDAR Mapping Forum in Denver, CO; and Commercial UAV Expo Americas in Las Vegas, NV.

“These synergies, in addition to our shared values and commitment to our customers through a long-term vision and industry expertise, make this a perfect fit,” remarked Diversified’s President & CEO, Theodore Wirth. “We are very pleased to welcome the event’s co-founders Luke Collings and Oliver Hughes and their talented show team to our growing UK division, under Managing Director Carsten Holm.”

Digital Construction Week is a growing event, known for its comprehensive, high-quality seminar and conference program and qualified attendees, who return year after year. The latest, and fourth edition, held at ExCeL in London on October 16-17 was the most successful to date. Doubling its 2017 attendance, it attracted 6,500 visitors, 200 exhibitors and 250 speakers, presenting across 6 stages with a dedicated conference stream.

Holm expressed that “having watched the evolving success of Digital Construction Week ever since Luke and Ollie launched it in 2015, we are proud to bring it into Diversified; and we are excited to provide the additional resources and support that will allow the team to continue to expand the event to further support the professionals and businesses within this growing and evolving industry.”

Including recent acquisitions and a series of new launches, Diversified UK continues to strengthen its position as one of the most successful tradeshow organizers in the UK. The award-winning UK division of Diversified Communications now employs over 110 staff members and has more than doubled in size over the past three years.

The next Digital Construction Week takes place at ExCeL London on October 17-18 2019.

Diversified Communications is a leading international media company with a portfolio of face-to-face exhibitions and conferences, online communities and digital and print publications. As producers of these market-leading products Diversified Communications connects, educates and strengthens business communities in over 15 industries including: food and beverage, healthcare, natural and organic, business management and technology. Established in 1949 and headquartered in Portland, Maine, USA with divisions and offices around the world, Diversified Communications remains a privately held, third generation, family-owned business. For more information, visit: http://www.divcom.com Reported by PRWeb 2 hours ago.

*INNATE PHARMA ANNOUNCES UPDATED RESULTS THAT SUPPORT ADVANCEMENT OF IPH4102 IN REFRACTORY SÉZARY SYNDROME AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) 2018 ANNUAL MEETING*

· *Differentiating profile of IPH4102 confirmed: high and durable response, favorable safety profile with long-term follow-up and substantial improvement in quality of life*
· *Innate Pharma expects to initiate a global Phase II study ("TELLOMAK") in different subtypes of T-cell lymphomas in the first half of 2019 *
· *Management to host KOL call Tuesday, December 4, 5pm CET (8am PST)*

*Marseille, France, December 3, 2018, 20:45 PM CET *

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), today announced updated data from the Phase I trial (including an expansion cohort) evaluating IPH4102 in refractory patients with Sézary syndrome (SS) and its plan to advance IPH4102 in a multi-cohort Phase II study in different subtypes of T-cell lymphoma. An oral presentation will take place on Monday, December 3, at the ASH 2018 Annual Meeting in San Diego, USA, by Pr Martine Bagot, Head of the Dermatology Department at the Saint Louis Hospital, Paris and Principal Investigator of the study. IPH4102 is Innate Pharma's wholly-owned first-in-class anti-KIR3DL2 antibody, designed for treatment of T-cell lymphoma.

As of October 15, 2018, data from the subgroup of 35 SS patients revealed strong clinical activity, demonstrated by an overall response rate (ORR) of 42.9%, median duration of response (DoR) of 13.8 months and median progression-free survival (PFS) of 11.7 months.

Mogamulizumab pretreated patients (n=7) showed an ORR (42.9%), median DoR (13.8 months) and median PFS (16.8 months) similar to the entire group. The ORR appeared to be higher (n = 28, 53.6%) in patients with no histologic evidence of large cell transformation (LCT)^[1].

"The solid updated data on IPH4102 presented today strongly encourage us to advance IPH4102 in refractory Sézary syndrome patients. We believe that the planned Phase II study, together with the Phase I data, has the potential to support a BLA submission in this indication," *commented **Pierre Dodion, Chief Medical Officer of Innate Pharma.* "In addition, the expression profile of KIR3DL2 provides a strong rational to explore the potential of IPH4102 in other subtypes of T-cell lymphomas in the TELLOMAK phase II study".

Importantly, clinical activity was associated with a substantial improvement in quality of life as assessed by the SkinDex29 and Pruritus Visual Analog Scale (VAS) scores. IPH4102 displayed a favorable safety profile, consistent with previous observations.

"Refractory Sézary syndrome patients have limited effective treatment options in later lines of therapy, with toxicity remaining an area of great concern with currently approved drugs," *commented Professor Martine Bagot, Principal Investigator of the study.* "IPH4102, in addition to demonstrating an impressive clinical activity, has shown a favorable safety profile and substantially improves the quality of life even in patients with stable disease. Translational results show relevant pharmacodynamics effects of IPH4102 in skin and in blood, which are in line with the clinical efficacy of the drug."

Exploratory biomarker analysis show early elimination of aberrant tumor cells and peripheral blood KIR3DL2+ CD4 T cells upon IPH4102 administration in responding patients.

The presentation is available in the IPH4102 section on Innate Pharma's website.

*KOL webcast and conference call on Tuesday, December 4, at 5pm CET (8am PST)*

Pierre Dodion, Chief Medical Officer, Innate Pharma, will be joined by Prof. Martine Bagot, Head of Dermatology Department at the Saint Louis Hospital, Paris and lead investigator of the study, for a live webcast and conference call with a Q&A session on Tuesday, December 4 at 5pm CET to discuss the announcement.

The presentation and access to the live webcast will be available at this link: https://edge.media-server.com/m6/p/229ej2mw

Participants can also join the conference call using the following dial-in numbers:

*Location* *Purpose* *Phone number*
France Participant +33 (0)1 76 77 22 57
United Kingdom Participant +44 (0)330 336 9411
United States Participant +1 929-477-0324
Standard International Access Participant 0800 279 7204

The participation code is: 4535688

An audio replay file will be made available after the session via Innate Pharma's website: www.innate-pharma.com

*About the IPH4102 Phase I trial: *

The Phase I trial (NCT02593045) is an open label, multicenter study of IPH4102 in patients with relapsed/refractory CTCL which is performed in Europe (France, Netherlands and United Kingdom) and in the US. Participating institutions include several hospitals with internationally recognized expertise: the Saint-Louis Hospital (Paris, France), the Stanford University Medical Center (Stanford, CA), the Ohio State University (Columbus, OH), the MD Anderson Cancer Center (Houston, Texas), the Leiden University Medical Center (Leiden, Netherlands), and the Guy's and St Thomas' Hospital (London, United Kingdom). Up to 55 patients with advanced CTCL having received at least two prior lines of systemic therapy were to be enrolled in two sequential study parts:

· The dose-escalation part has accrued 25 KIR3DL2-positive CTCL patients at 10 dose levels. The objective was to characterize IPH4102 safety profile and to identify the MTD and/or the RP2D; the dose-escalation followed an accelerated 3+3 design. Safety data of all dose levels were presented at the ICML meeting on June 14, 2017. Final results of the dose-escalation part were presented at the EORTC CLTF Meeting on October 15, 2017.
· The cohort expansion enrolled 19 patients with Sézary Syndrome (n=15) and tMF (n=4) receiving IPH4102 at the RP2D until progression.

The primary objective of this trial was to evaluate the safety and tolerability of repeated administrations of single agent IPH4102 in this patient population. The secondary objectives included assessment of the drug's antitumor activity. Clinical endpoints included global objective response rate, response duration and progression-free survival. Exploratory analyses are aimed at identifying biomarkers of clinical activity.

*About IPH4102:*

IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed for treatment of CTCL, an orphan disease. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few therapeutic options at advanced stages.   KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up to 85% of them with certain aggressive CTCL subtypes, in particular, Sézary syndrome and transformed mycosis fungoides. It has a restricted expression on normal tissues.

IPH4102 was granted orphan drug status in the European Union and in the United States for the treatment of CTCL.

*About Cutaneous T-Cell Lymphoma ("CTCL"):*

CTCL is a heterogeneous group of non-Hodgkin's lymphomas which arise primarily in the skin and are characterized by the presence of malignant clonal mature T-cells. CTCL accounts for approximately 4% of all non-Hodgkin's lymphomas and has a median age at diagnosis of 55-65 years.

Mycosis fungoides, and Sézary syndrome, its leukemic variant, are the most common CTCL subtypes. The overall 5-year survival rate, which depends in part on disease subtype, is approximately 10% for Sézary syndrome and less than 15% for transformed mycosis fungoides. CTCL is an orphan disease and patients with advanced CTCL have a poor prognosis with few therapeutic options and no standard of care. There are approximately 6,000 new CTCL cases in Europe and the United States per year.

*About Peripheral T-Cell Lymphoma ("PTCL"):*

PTCL represents a group of non-Hodgkin lymphomas of mature T-cell origin with generally aggressive clinical behavior (Armitage, 2015). The three predominant aggressive PTCL subtypes in the Western countries are: PTCL not otherwise specified (NOS); angioimmunoblastic T cell lymphoma (AITL); and anaplastic T cell lymphoma (ALCL). In aggregate, PTCL accounts for approximately 10% of all non-Hodgkin's lymphomas and has a median age at diagnosis around 65 years.

Multi-agent chemotherapy is the recommended first line treatment for the majority of patients with PTCL (NCCN guidelines). Brentuximab vedotin has been recently approved by the US FDA in combination with first line chemotherapy for patient with CD30 positive PTCL (FDA press release, Nov 16, 2018). Stem cell transplantation (SCT) is a potentially curative option but is rather restricted to a minority of patients who are young, fit and achieve complete response to systemic therapy (Wilhelm, Smetak et al. 2016). Hence a high proportion of patients need second line therapy. Belinostat, pralatrexate and romidepsin have been approved by the FDA in this setting, but efficacy is generally limited (O'Connor, Zcan et al. 2015). None of these treatments have been approved by EMA. Brentuximab vedotin is also approved in the 2nd line setting (Pro, Advani et al. 2017), but if used in the first line, it may no longer be an option in 2nd line patients.

*About Innate Pharma:*

Innate Pharma S.A. is a fully integrated oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma's commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma's broad pipeline of antibodies includes several first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a landmark and multi-products partnership with
AstraZeneca/MedImmune. 

Based in Marseille, France, Innate Pharma is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com

*Information about Innate Pharma shares:*

*ISIN code*
*Ticker code*
*LEI* FR0010331421
IPH
9695002Y8420ZB8HJE29

*Disclaimer:*

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website www.amf-france.org or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

*For additional information, please contact:*

*Investors*

* *

*Innate Pharma  *

Dr. Markus Metzger / Danielle Spangler /
Jérôme Marino

Tel.: +33 (0)4 30 30 30 30

investors@innate-pharma.com

* * *International Media *

* *

*Consilium Strategic Communications *

Mary-Jane Elliott / Jessica Hodgson

Tel.: +44 (0)20 3709 5700

InnatePharma@consilium-comms.com
* * *French Media*

* *

*ATCG Press *

Marie Puvieux

Mob: +33 (0)6 10 54 36 72

presse@atcg-partners.com

* *
^[1] LCT is present in approximatively 10% of Sézary syndrome patients (Talpur, CLML 2016) and is associated with poorer prognosis and shorter survival.

*Attachment*

· PR in English.pdf Reported by GlobeNewswire 2 hours ago.

The managing director of East Palo Alto-based Woodside Capital Partners predicts consolidation is coming in the autonomous driving future that is shaping up differently in the U.S., China and Europe. Reported by bizjournals 56 minutes ago.

Bentley, which previously appeared more than ready to launch an electric car, has pumped the brakes. The brand's CEO Adrian Hallmark told Automotive News Europe (subscription required) in a Monday report that the company wants to wait for battery technology to advance. Today, and in the near future, the battery technology needed to produce an... Reported by MotorAuthority 2 hours ago.